Login to Your Account



Preclinical Oncogene Target

Loxo Winner: Array's Cancer Pact Valued as High as $434M

By Randy Osborne
Staff Writer

Wednesday, July 10, 2013
deals_and_ma.jpg

Newly formed by the venture firm Aisling Capital, Loxo Oncology Inc. has entered a deal with Array Biopharma Inc. to advance a preclinical candidate developed by Array and to find more small-molecule drugs for oncology targets.

The arrangement could mean as much as $434 million in milestone payments as well as royalties on any resulting products for Boulder, Colo.-based Array, which also received shares of Loxo as part of the deal.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription